



# LUND UNIVERSITY

## Apolipoprotein M – Studies of Structure and Function

Ahnström, Josefin

2009

[Link to publication](#)

*Citation for published version (APA):*

Ahnström, J. (2009). *Apolipoprotein M – Studies of Structure and Function*. [Doctoral Thesis (compilation), Clinical Chemistry, Malmö]. Department of Clinical Chemistry, Lund University.

*Total number of authors:*

1

### General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

# Apolipoprotein M

*Studies of Structure and Function*

Josefin Ahnström

Doctoral Thesis



LUND UNIVERSITY

Faculty of Medicine

Division of Clinical Chemistry  
Department of Laboratory Medicine, Malmö  
Faculty of Medicine  
Lund University  
2009

*The picture of the apoM structure on  
the cover is made by Dr Madhumati Sevvana.*

# Apolipoprotein M

*Studies of Structure and Function*

Josefin Ahnström



LUND UNIVERSITY

Faculty of Medicine

Akademisk avhandling  
som med vederbörligt tillstånd av Medicinska Fakulteten vid  
Lunds Universitet för avläggande av doktorsexamen i  
laboratoriemedicin med inriktning klinisk kemi kommer att  
offentligen försvaras i föreläsningssalen ingång 78 (under  
skärmtaket), plan 2, Universitetssjukhuset MAS, Malmö,  
fredagen den 25:e September 2009, kl 9.00.

Fakultetsopponent: Professor Gert M. Kostner,  
Medical University of Graz, Graz, Austria

Organization LUND UNIVERSITY  Department of Laboratory Medicine Clinical Chemistry Malmö University Hospital S-20502 Malmö, Sweden	Document name DOCTORAL DISSERTATION	
Author(s) Josefin Ahnström	Date of issue September 5, 2009	
	Sponsoring organization	
Title and subtitle  Apolipoprotein M – Studies of Structure and Function		
<p>Abstract          Apolipoprotein M (apoM), a 25 kDa plasma protein, is found in all major lipoprotein classes, although the majority is found in high density lipoproteins (HDL). ApoM has been suggested to be involved in the formation of and adding to the antiatherogenic functions of HDL, but its function is still not completely known.</p> <p>ApoM has been suggested to be a lipocalin. By studies in vitro using recombinant apoM we were able to show that apoM shares the ligand-binding abilities of lipocalins by being able to bind retinol and its two metabolites, all-trans retinoic acid and 9-cis retinoic acid. After successful crystallization trials we managed to determine the 3D structure of recombinant apoM expressed in E.coli. ApoM displays the typical lipocalin fold, i.e. characterized by an 8-stranded antiparallel <math>\beta</math>-barrel enclosing an internal ligand-binding pocket, flanked by a <math>\alpha</math>-helix. The ligand-binding pocket in apoM can be subdivided into a hydrophilic upper part and a hydrophobic lower part. ApoM was crystallized as a complex with either myristic acid or glycerol-1-myristate in the hydrophobic pocket showing that apoM can work as a fatty acid binding protein. We were also able to detect a binding of D-sphingosine and sphingosine-1-phosphate in ligand-binding studies. The physiological importance of the binding is not known.</p> <p>Mature apoM is circulating with a retained signal peptide. By constructing apoM with a cleavable signal peptide we were able to show that the signal peptide is necessary for the protein's ability to associate to lipoproteins. We were also able to show that, in contrast to apoM with a cleavable signal peptide, full-length apoM was accumulated in stably transfected HEK293 cells, expressing apoM, unless serum was present. The addition of extra cellular HDL or co-expression of HDL was enough to completely restore the apoM expression.</p> <p>We have in a previous study found a marked positive correlation between plasma apoM and total cholesterol levels in healthy individuals. To investigate whether plasma apoM levels predict the risk of coronary heart disease, apoM was measured in plasma from subject later developing CHD and healthy controls from two prospective case-control studies, FINRISK '92 and Copenhagen City Heart Study. In conditional logistic regression analyses, apoM was not a predictor of CHD events. We found positive correlations for apoM with both apoA-I and apoB.</p>		
Key words: Apolipoprotein, lipocalin, crystallization, signal peptide, signal peptidase, HDL, coronary heart disease		
Classification system and/or index termes (if any):		
Supplementary bibliographical information:	Language	
ISSN and key title: 1652-8220	ISBN 978-91-86253-64-6	
Recipient's notes	Number of pages 120	Price
	Security classification	

Distribution by (name and address)

I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

Signature

*Josefin Ahnström*

Date August 16, 2009

*Man can't help hoping even if he is a scientist.  
He can only hope more accurately.  
--Karl A. Menninger*



# CONTENTS

CONTENTS	7
LIST OF PAPERS	9
ABBREVIATIONS	10
INTRODUCTORY WORDS	13
LIPOPROTEINS AND THEIR METABOLISM	14
Lipoproteins in cardiovascular diseases	18
APOLIPOPROTEINS	19
Apolipoproteins in cardiovascular diseases	21
LIPOCALINS	23
Structure	24
Ligand-binding	25
APOLIPOPROTEIN M	26
The gene regulation of apoM	26
The structure and ligand-binding abilities of apoM (Papers I-II)	28
The apoM signal peptide (Papers III-IV)	32
The apoM particle	34
ApoM in the kidney	35
ApoM in mice	36
ApoM in humans	37
ApoM in diabetes	37



ApoM in cardiovascular diseases (Paper V)	38
FUTURE PERSPECTIVES	40
POPULAR SCIENTIFIC SUMMARY	42
POPULÄRVETENSKAPLIG SAMMANFATTNING	45
ACKNOWLEDGEMENTS	48
BIBLIOGRAPHY	50
APPENDICES: (Papers I-V)	71

## LIST OF PAPERS

This thesis is based on the following papers, which are referred to in the text by their roman numerals:

- I. **Ahnström J., Faber K., Axler O. and Dahlbäck B.** Hydrophobic ligand-binding properties of the human lipocalin apolipoprotein M. *J Lipid Res* 2007. 48: 1754–1762.
- II. **Sevvana M.\*, Ahnström J.\*, Egerer-Sieber C., Dahlbäck B. and Muller Y.A.** Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apoM. *Submitted manuscript*.
- III. **Axler O., Ahnström J., and Dahlbäck B.** Apolipoprotein M associates to lipoproteins through its retained signal peptide. *FEBS Lett* 2008. 582(5): 826–828.
- IV. **Ahnström J., Axler O. and Dahlbäck B.** HDL stimulates ApoM secretion. *Submitted manuscript*.
- V. **Ahnström J.\*, Axler O.\*, Jauhiainen M., Salomaa V., Havulinna A., Ehnholm C., Frikke-Schmidt T., Tybjaerg-Hansen A., and Dahlbäck B.** Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent prospective case-control studies. *J Lipid Res* 2008. 49(9): 1912–1917.

\*Authors contributed equally to this work.

Published papers are reprinted with the permission of the respective copyright holders.

## ABBREVIATIONS

ABCA1	ATP-binding cassette A1
ABCG1	ATP-binding cassette G1
apoA-I	Apolipoprotein A-I
apoA-II	Apolipoprotein A-II
apoB	Apolipoprotein B
apoB-48	Apolipoprotein B-48
apoB-100	Apolipoprotein B-100
apoC	Apolipoprotein C
apoD	Apolipoprotein D
apoE	Apolipoprotein E
apoM	Apolipoprotein M
Arg	Arginine
Asp	Asparagine
BMI	Body mass index
CCHS	Copenhagen City Heart Study
CETP	Cholesterol ester transfer protein
CHD	Coronary heart disease
CVD	Cardiovascular disease
Glu	Glutamine
HDL	High density lipoprotein
HDL-c	HDL-cholesterol
HEK293	Human embryonic kidney 293
HNF-1 $\alpha$	Hepatocyte nuclear factor 1-alpha
IC <sub>50</sub>	Half maximal inhibitory concentration
IDL	Intermediate density lipoproteins
LCAT	Lecithin:cholesterol acyltransferase
LDL	Low density lipoprotein

LDL-c	LDL-cholesterol
LDLr	LDL-receptor
LPL	Lipoprotein lipase
LRH-1	Liver receptor homolog 1
LRP	LDLr-related protein
LTA	Lymphotoxin alpha
LXR	Liver X receptor
MHC	Major histocompatibility complex
MI	Myocardial infarction
MODY	Maturity onset of diabetes in the young
MUP	Major urinary protein
NGAL	Neutrophil-gelatinase associated lipocalin
PAF	Platelet-activating factor
PON-1	Paraoxonase-1
RBP	Retinol binding protein
SAA	Serum amyloid A
SNP	Single-nucleotide polymorphism
SR-B1	Scavenger receptor type B1
TNF	Tumor necrosis factor
TGF- $\alpha$	Transforming growth factor-alpha
TGF- $\beta$	Transforming growth factor-beta
Trp	Tryptophan
VCAM-1	Vascular cell adhesion molecule-1
VLDL	Very low density lipoprotein



## INTRODUCTORY WORDS


This thesis will give you a short introduction to the lipid metabolism, the most common apolipoproteins and the lipocalin protein family. The focus will be on one of our apolipoproteins and lipocalins, apolipoprotein M (apoM), the protein I have been working with during my PhD studies. ApoM is a protein that was discovered only 10 years ago. In this thesis you will get a summary of what is known about apoM today, and what I have been spending the last four years doing.

## LIPOPROTEINS AND THEIR METABOLISM

Fat is the main source of energy that is transported between different organs. As fat is insoluble in water it is transported in blood in the form of lipoproteins.<sup>1,2</sup> Lipoproteins are complexes formed by fat and specific proteins (apolipoproteins). Each particle consists of a hydrophobic core of mainly triglycerides and esterified cholesterol, surrounded by a shell of amphiphilic molecules, phospholipids, unesterified cholesterol and apolipoproteins (Figure 1).<sup>1,2</sup> The traditional definition of the lipoprotein classes is based on their density or, alternatively, their electrophoretic mobility.<sup>1,3</sup> When classified according to increasing density they are divided into chylomicrons, very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipoproteins (LDL) and high density lipoproteins (HDL).<sup>1-3</sup> Because of the lack of standardized isolation procedures, the end products might not necessarily be identical from one laboratory to another. By electrophoretic criteria, serum lipoproteins may also be classified according to their mobility in electric fields. The correspondences to the ultracentrifugal classes are indicated in Table 1. Even though the lipoproteins are divided into different classes these are not distinct populations. All lipoproteins are parts of the same system with a constant exchange of contents and are being formed or degraded at different rates (Figure 2).<sup>1</sup>

**Chylomicrons** are large, triglyceride rich particles, formed in the intestinal mucosal cells, and are only present in the

circulation after food intake.<sup>1,4</sup> Their main apolipoprotein is apolipoprotein B-48 (apoB-48). The chylomicrons transport fat from the intestine to the tissues, where they are rapidly metabolized by lipoprotein lipase (LPL). The chylomicron remnants are readily taken up by the liver by the LDL-receptor (LDLr) and the LDLr-related protein (LRP).<sup>4,5</sup>



**Figure 1.** Lipoproteins are composed of a hydrophobic lipid core filled with esterified cholesterol molecules and triglycerides. Phospholipids, free cholesterol, and apolipoproteins form the outer surface of the lipoprotein particles. The image was originally published in *Atlas of Heart Diseases: Cardiovascular Risk Factors* by Gornik H., Plutzky J.<sup>6</sup> and is reprinted here with kind permission from Current Medicine Group LLC.

**VLDL, IDL and LDL** transport endogenous fat from the liver to the other tissues, mainly adipose tissues, heart and muscles.<sup>2</sup> VLDL is formed in the liver with apolipoprotein B-100 (apoB-100) as the main apolipoprotein. The half time of VLDL is, as for chylomicrons, very short. Most of the triglycerides are




taken up by the tissues, and the remaining content is forming an IDL particle that is quickly hydrolyzed to LDL.<sup>4,5</sup> In fact, the half time of IDL is so short (minutes) that the levels in plasma are normally almost undetectable.<sup>1</sup> LDL, in contrast to VLDL and IDL, has a fairly long half time (3-4 days). LDL are triglyceride-poor, cholesterol-rich particles and contain about 70% of the fat present in the circulation.<sup>1</sup> LDL transports cholesterol to tissues via the binding to the LDL receptors.<sup>4</sup>

**HDL** is a group of smaller, protein rich lipoprotein particles that contain apolipoprotein A-I (apoA-I) and/or apolipoprotein A-II (apoA-II). About 70% of the total HDL protein is apoA-I, and 20% is apoA-II.<sup>7,8</sup> HDL are heterogeneous, comprising several subpopulations of particles that vary in shape, size, density and surface charge. They contain around 25% of the cholesterol present in plasma.<sup>1</sup> HDL particles have a scavenger by taking up surface components from the other lipoprotein classes, but they are also crucial for the transport of excess cholesterol from peripheral tissues back to the liver, the reverse cholesterol transport.<sup>8-13</sup> Most HDL particles are spherical and  $\alpha$ -migrating, and are called HDL<sub>2</sub> ( $1.063 < d < 1.125$  g/ml) or HDL<sub>3</sub> ( $1.125 < d < 1.21$  g/ml). HDL<sub>2</sub> are larger and contain more types of proteins than HDL<sub>3</sub>.<sup>1,8,14</sup> There are also minor  $\gamma$ -migrating subpopulations of HDL particles containing only apolipoprotein E (apoE).<sup>8,11,15</sup> HDL can be formed either from the liver, intestine or from fragments of other lipoproteins.<sup>10</sup>

**Table 1.** Properties of the plasma lipoproteins.<sup>1,3,11,15</sup>

Parameter	Chylomicrons	VLDL	IDL	LDL	HDL
Electrophoretic mobility	Origin	Pre- $\beta$	$\beta$	$\beta$	Pre- $\beta$ , $\alpha$ , $\gamma$
Density (g/ml)	<0.94	0.94-1.006	1.006-1.019	1.006-1.063	1.063-1.21
Main apolipoprotein	B-48	B-100	B-100	B-100	A-I
Main function	Transport of exogenous fat	Transport of endogenous triglycerides	Precursor for LDL	Transport of cholesterol	Reverse cholesterol transport



**Figure 2.** Schematic overview of the metabolism of the plasma lipoproteins and reverse cholesterol metabolism. The image was originally published in *Atlas of Heart Diseases: Atherosclerosis* by Brewer B.H.<sup>16</sup> and is reprinted here with kind permission from Current Medicine Group LLC.

Newly formed HDL particles are discoidal and are often called nascent HDL or pre-β-HDL. Discoidal HDL particles consist only of surface constituents arranged as a molecular bi-layer of phospholipids and unesterified cholesterol encircled by one or two molecules of apoA-I.<sup>8,10,17,18</sup> With help from various enzymes, pre-β-HDL particles acquire their lipid contents and form spherical HDL particles. Enzymes involved in these reactions include the ATP-binding cassette A1 (ABCA1), ATP-binding cassette G1 (ABCG1), scavenger receptor type B1 (SR-B1), lecithin:cholesterol acyltransferase (LCAT) and cholesterol ester transfer protein (CEPT) (Figure 2).<sup>1,8-11,13,19</sup>

## **Lipoproteins in cardiovascular diseases**

Cardiovascular disease (CVD) is the leading cause of death in the world.<sup>20</sup> The involvement of plasma cholesterol in the development and progression of atherosclerotic cardiovascular risk is well known and accepted. A positive relationship between LDL-cholesterol (LDL-c) and the risk of cardiovascular events has been observed in many large population studies, as has the inverse correlation for HDL-cholesterol (HDL-c).<sup>21-28</sup>

Atherosclerosis is a chronic inflammatory disorder occurring in the artery wall and is ultimately responsible for myocardial infarction, stroke and peripheral vascular disease. The molecular and cellular mechanisms for the pathobiological changes that lead to the disease are still poorly understood and several hypotheses have been articulated to explain the events that initiate atherogenesis.<sup>29</sup> A hallmark is the accumulation of cholesterol in arterial macrophages.<sup>30,31</sup> LDL is the main atherogenic lipoprotein in plasma. If the plasma concentration of LDL is high enough it does not only infiltrate but also accumulate in the arterial intima.<sup>30,31</sup> Modification of LDL, through oxidation or enzymatic attack in the intima, activates endothelial cells and evokes the immune system, causing an inflammation and the formation of an atherosclerotic plaque.<sup>21,30,32-34</sup> HDL is antiatherogenic, both by being anti-oxidant and anti-inflammatory. HDL particles are believed to protect against atherosclerosis by mediating the return of excess tissue cholesterol to the liver for secretion in bile.<sup>35-37</sup> However, HDL has more roles than the ones in plasma cholesterol transport. It is also known that HDL inhibits the formation of oxidized LDL, promotes cholesterol from arterial macrophages and inhibits the expression of adhesion proteins, e.g. vascular cell adhesion molecule-1 (VCAM-1) and E-selectin.<sup>8,38-40</sup> The molecular basis for these functions is still not fully understood, let alone less mapped to the different components of the HDL particle.<sup>41,42</sup> Myocardial infarction (MI) occurs when the atheromatous process prevents blood flow through the coronary artery.<sup>31,34</sup> The infarction is mostly caused by the formation of an occluding thrombus on the surface of the plaque. The thrombosis in turn is caused by plaque rupture and endothelial erosion.<sup>30,31,43</sup>

## APOLIPOPROTEINS

Apolipoproteins, the protein components of lipoproteins, have three main functions. 1) They help stabilize apolar lipids in plasma. 2) They bind to cell surface receptors and thereby determine the sites of cellular uptake and degradation of lipoproteins. 3) They regulate the activity of enzymes involved in the lipid metabolism.<sup>44,45</sup> The main apolipoproteins are of the subclasses A, B, C, D or E. They all have different metabolic functions.<sup>46</sup> More apolipoprotein have been identified (apoF - apoO), but little is known about their functions.

**ApoA-I** and **apoA-II** are the major HDL proteins (Table 2).<sup>47</sup> In addition to binding lipids, apoA-I enhances the activity of LCAT. The main function of apoA-II is not known.<sup>48</sup> The plasma concentration of apoA-I in humans is around 1 mg/ml, making it one of the most abundant proteins in human plasma.<sup>8</sup> Although apoA-I is often used to estimate the HDL levels, apoA-I is exchanged between lipoproteins and the number of apoA-I molecules varies between particles. ApoA-II is the second most abundant apolipoprotein of HDL.<sup>48</sup> It binds to phospholipids with higher affinity than does apoA-I and is found mainly in the spherical HDL particles.<sup>8,47</sup>

**Apolipoprotein B** (apoB) is a large amphipathic protein existing in two forms, apoB-100 and apoB-48. It is essential for the intracellular assembly of VLDL and chylomicrons in the secretory pathway of the cells.<sup>49,50</sup> ApoB-48 corresponds exactly to the N-terminal 48% of apoB-100.<sup>49-51</sup> ApoB-100 is found on the surface of VLDL, IDL and LDL, whereas apoB-48 is only present

on chylomicrons.<sup>49,50</sup> Structural aspects of apoB-100 are difficult to study because of its huge size (512 kDa) and insoluble nature once it is separated from its lipid environment.<sup>51</sup> One apoB-100 molecule is found on each particle making it possible to use apoB as a measurement of the number of LDL or VLDL particles present in plasma.<sup>29</sup> Normally, more than 90% of plasma apoB-100 is bound to LDL, and the remainder to VLDL.

**Apolipoproteins C** (apoC) exists in three different isoforms in humans, C-I, C-II and C-III (Table 2).<sup>52-54</sup> They are all present in chylomicrons, VLDL and HDL.<sup>53</sup> Several functions of apoC-I have been documented. ApoC-I inhibits the uptake of triglyceride rich lipoproteins via hepatic receptors, particularly by LRP.<sup>53,55,56</sup> ApoC-I is also involved in HDL remodeling by activation of LCAT and inhibition of CETP.<sup>55,56</sup> C-II is the key cofactor for LPL.<sup>57,58</sup> The sequence for the activation of LPL reside in the C-terminal domain of the apoC-II peptide.<sup>59</sup> ApoC-III is the most abundant of the C-apolipoproteins in humans (Table 2). ApoC-III inhibits LPL and LDLr-mediated endocytosis of lipoprotein particles.<sup>46,52</sup> The attenuated clearance of triglyceride rich lipoproteins is associated with increased coronary risk and the induction of myocardial ischemia.<sup>58,60</sup>

**Apolipoprotein D** (apoD) occurs mainly in HDL although it is present also in LDL and VLDL.<sup>48,61</sup> ApoD has long been predicted to be a member of the lipocalin protein family.<sup>61-64</sup> In 2007, Eichinger *et al* were able to solve the crystal structure for free apoD, and its complex with progesterone, confirming the lipocalin fold.<sup>65</sup> *In vitro* studies have shown that apoD is able to bind cholesterol, progesterone, bilirubin and arachidonic acid, although, as for many lipocalins, the physiological ligand is unknown.<sup>61,65-68</sup> The function of apoD is not known but it has been suggested to be a multi-ligand, multi-functional transporter.<sup>61</sup>

**ApoE** is a polymorphic 34.2 kDa protein (Table 2).<sup>70</sup> It is a crucial ligand for receptor-mediated uptake of chylomicron remnants and IDL, binding the lipoproteins to several receptors including the LDLr, LRP and the VLDL-receptor.<sup>44,45,47,71</sup> ApoE has two structural domains: a 22 kDa N-terminal domain

**Table 2.** Properties of the major plasma apolipoproteins<sup>1,8,49,61,69</sup>

Protein	Lipoprotein	Function	Concentration	Site of expression
A-I	HDL, chylomicrons	Activate LCAT	1-2 g/l	Liver, intestine
A-II	HDL	Not known	300-400 mg/l	Liver
B-48	chylomicrons	Secretion of chylomicrons and uptake of chylomicron remnants in the liver	-	Intestine
B-100	VLDL, IDL, LDL	VLDL secretion, uptake of LDL	0.5-1.2 g/l	Liver
C-I	HDL, VLDL, chylomicrons	Inhibits uptake of lipoproteins by hepatic receptors. Activates LCAT and inhibits CETP.	~60 mg/l	Liver
C-II	HDL, VLDL, chylomicrons	Activates LPL	~40 mg/l	Liver
C-III	HDL, VLDL, chylomicrons	Inhibits LPL	~120 mg/l	Liver
D	HDL	Not known	~120 mg/l	Adrenal glands, pancreas, kidneys, placenta, spleen, lungs, ovaries, testes, brain, peripheral nerves and cerebrospinal fluid
E	IDL, chylomicron remnants	Uptake of lipoproteins in cells	30-70 mg/l	Liver

containing the LDLr binding region and a 10 kDa C-terminal domain that contains the major lipid- or lipoprotein binding elements.<sup>44,70</sup> There are three common isoforms of apoE: E2, E3 and E4.<sup>72,73</sup> ApoE3, the most abundant isoform, is considered the “parent” protein.<sup>44</sup> ApoE4 has been identified as a major risk factor for Alzheimer’s disease.<sup>70,74,75</sup> Despite intense research, the

molecular mechanisms underlying the association of apoE4 with Alzheimer's disease is not clear.<sup>75</sup>

### **Apolipoproteins in cardiovascular diseases**

Lately there have been a number of studies regarding which is more important for predicting CVD – the cholesterol that HDL and LDL carry, or the actual particle count, measured as apoA-I and apoB.<sup>76-81</sup> Several studies have suggested that apoA-I and apoB are better predictors for coronary heart disease (CHD) and MI than lipoprotein levels.<sup>76-78,80,81</sup> In a Danish population study, based on the Copenhagen City Heart study (CCHS), we showed that apoA-I and apoB were just as good at predicting the development of CHD as HDL and LDL.<sup>82</sup>

## LIPOCALINS


The lipocalin family is a large, and expanding, group of proteins. They are typically small (150-250 amino acid residues), extracellular proteins and their physiological role usually lies in the transport or storage of hydrophobic and/or chemically sensitive compounds (e.g. vitamins, lipids and steroids).<sup>83-85</sup> They share several common molecular recognition properties: the binding of small, principally hydrophobic molecules (such as retinol); binding to specific cell-surface receptors (such as megalin); and the formation of covalent and non-covalent complexes with other soluble macromolecules (such as the retinol binding protein (RBP)-transthyretin complex).<sup>83-85</sup> Lipocalins occur in many organisms, such as vertebrates, insects and plants, and even in bacteria.<sup>83,86</sup> Although they have been classified as transport proteins it is now clear that members of the lipocalin family fulfill a wide variety of different functions. Roles include retinol transport, cryptic coloration, pheromone transport, and the enzymatic synthesis of prostaglandins.<sup>85,87-90</sup> The lipocalins have also been implicated in the regulation of the immune response<sup>91</sup> and the mediation of cell regulation.<sup>92</sup> Their wide variety of functions are also reflected in the use of several lipocalins as biochemical markers of disease. Clinical indications relate to almost any medical field, such as inflammatory disease, cancer and lipid disorders as well as liver and kidney function.<sup>93</sup>



## Structure

The amino acid sequences of lipocalins in general show a low percentage (below 20%) of similarity between members but they share a well-conserved three-dimensional structure.<sup>94,95</sup> The lipocalin fold consists of an eight-stranded antiparallel  $\beta$ -barrel, flanked by an  $\alpha$ -helix (Figure 3). In cross-section, the barrel has a flattened or elliptical shape that encloses an internal ligand-binding site.<sup>85,94,96</sup> The eight  $\beta$ -strands are linked by seven loops, all typical short  $\beta$ -hairpins, except the first loop which is a large  $\Omega$  loop which forms a lid that partially or completely closes the ligand-binding site.<sup>84,85</sup> The conserved folding is partly accounted for by a highly conserved gene structure with a typical seven exons/six introns arrangement. Exons 2-5, whose sizes are a typical feature of lipocalin genes, code for the entire set of  $\beta$ -strands.<sup>97</sup>

Most lipocalins, the kernel lipocalins, share three characteristic structurally conserved regions<sup>84</sup> while other more divergent family members, the outlier lipocalins, share only one or two.<sup>84,98</sup> RBP and apoD, two lipocalins of known three-dimensional structure, are kernel lipocalins (Figure 3).<sup>65,98,99</sup> A tryptophan at the bottom of the ligand-binding pocket is highly conserved in lipocalins. Extensive structural studies of RBP showed that lack of this tryptophan (Trp24) leads to losses in stability and decreased yields of protein when refolding *in vitro* while it was not needed for maintaining the function of the protein.<sup>100</sup>



**Figure 3.** Ribbon representation of the crystal structures of the human lipocalins RBP and apoD.<sup>65,99</sup>

## Ligand-binding

The large cup-shaped cavity within the  $\beta$ -barrel is well adapted for ligand-binding. The selectivity is determined by the amino acid composition of the pocket and the loop scaffold, as well as their overall size and conformation.<sup>94</sup> The binding site can form a wide, funnel-like opening, as in neutrophil gelatinase-associated lipocalin (NGAL).<sup>101,102</sup> Alternatively, the loops can close the cavity within the  $\beta$ -barrel and fully encapsulate the ligand, as for major urinary protein (MUP).<sup>89,103</sup> That pH-induced structural changes can affect the binding affinity has been shown for several lipocalins and their ligands.<sup>98</sup> Many lipocalins bind molecules with critical biological functions, e.g. retinoids, arachidonic acid and various steroids. Lipocalins with known endogenous ligands include RBP, which binds retinol,<sup>90,104</sup> MUP, which binds odorants in urine from male mice<sup>89</sup> and histamine-binding proteins, which have been shown to bind histamine.<sup>105</sup> However, it is important to draw a distinction between the demonstration of a binding *in vitro* and the identification of endogenous ligands. For example, the retinol binding exhibited by various lipocalins<sup>66,94</sup> may reflect a general affinity for a range of different small hydrophobic ligands. A broad selectivity of binding may reflect a general transport role, such as the clearance of unwanted compounds and can even give rise to pathological conditions.<sup>94,106</sup> Alpha 2u-N is a syndrome in male rats that are exposed to a number of environmental chemicals and pharmacological agents. The disease is caused by binding of these chemicals or their metabolites to alpha 2u, which, in turn, is believed to lead to a less digestible chemical-protein complexes.<sup>106</sup> Gutiérrez *et al.* suggested that more recently evolved lipocalins tend to show 1) show a greater rate of amino acid substitutions, 2) have a more flexible protein structure based on the number of disulfide bonds, and 3) bind smaller hydrophobic ligands to increase the efficiency of their ligand-binding contacts.<sup>107</sup> This can be used in drug-development where the use of lipocalins to design artificial binding proteins, anticalins, has become a new class of potential drugs for medical therapy.<sup>96,108-110</sup>

## APOLIPOPROTEIN M

ApoM is a 25 kDa plasma protein expressed in liver and kidney.<sup>111-113</sup> It was first discovered in 1999 in chylomicrons but is mainly associated with HDL particles.<sup>111</sup> The three-dimensional structure has, until now, not been experimentally determined but apoM is identified as a lipocalin with the ability to bind small lipophilic substances.<sup>114,115</sup> The function of apoM is today, 10 years after its discovery, unknown but several studies have suggested that apoM has antiatherogenic and anti-inflammatory functions.<sup>116-119</sup>

### **The gene regulation of apoM**

The human apoM gene is located on chromosome 6, at position p21.3 in the major histocompatibility complex (MCH) class III region.<sup>111</sup> The apoM gene is surrounded by *BAT4* and *NG34* on one side and *BAT3* on the other.<sup>111</sup> The MHC contains genes essential to both the adaptive and innate immune systems.<sup>120</sup> The class III region is the most gene-dense region of the human genome.<sup>121</sup> By the use of comparative analysis it has been shown that a cluster of MHC genes including, tumor necrosis factor (*TNF*), lymphotoxin alpha (*LTA*) (or its putative teleost homolog (*TNF-N*), *BAT3* and *apoM* have remained together for over 450 million years, predating the divergence of mammals from fish.<sup>120</sup> The importance of this is unknown.

**Hepatocyte nuclear factor 1-alpha** (HNF-1 $\alpha$ ) is a transcription factor involved in the regulation of a large set of hepatic genes, including albumin, and  $\alpha$ 1-antitrypsin. Patients with

maturity onset of diabetes in the young (MODY) type 3 carry mutations in the *HNF-1 $\alpha$*  gene in the heterozygous state.<sup>122</sup> In addition to being an important regulator of insulin secretion, HNF-1 $\alpha$  is an essential transcriptional regulator of bile acid and HDL-c metabolism.<sup>123</sup> HNF-1 $\alpha$  binds to the apoM gene promoter and HNF-1 $\alpha$  deficient mice have no or little apoM expression.<sup>124,125</sup> Also, as will be discussed below, an association between apoM plasma levels and MODY3 has been suggested, but the results are conflicting.<sup>124,126,127</sup>

The **liver receptor homolog 1** (LRH-1) has been reported to play an important role in bile acid biosynthesis<sup>128,129</sup> and reverse cholesterol transport.<sup>130-132</sup> It has also been suggested to be a negative regulator of the hepatic acute-phase response by inhibiting interleukin-6 and serum amyloid A (SAA).<sup>133</sup> There is a LRH-1 response element in both the human and the mouse promoter region of apoM and LRH-1 regulates apoM transcription in cultured cells.<sup>134</sup> Venteclef *et al.* has demonstrated that bile acids suppress apoM expression by inhibiting LRH-1 transcriptional activity.<sup>134</sup>

**Foxa2** belongs to the Foxa superfamily of winged helix/forkhead box (Fox) transcription factors, which has three members: Foxa1, Foxa2 and Foxa3.<sup>135</sup> They control embryonic development and organogenesis of liver, pancreas, brain, lung, thyroid and prostate.<sup>135-140</sup> A Foxa2 binding site was identified in the *apoM* promoter region at position -474.<sup>141</sup> It was also shown that haploinsufficient Foxa2<sup>+/-</sup> mice have decreased apoM expression.<sup>141</sup> The Foxa2<sup>+/-</sup> mice in addition have decreased HDL and pre $\beta$ -HDL levels.<sup>141</sup>

The **liver X receptor** (LXR) belongs to the nuclear receptor family and is a ligand-activated transcription factor involved in the regulation of lipid metabolism and inflammation.<sup>144,145</sup> The apoM expression was downregulated both in HepG2 cell cultures and *in vivo* in mice after addition of a LXR agonist.<sup>146</sup> A similar effect was seen after addition of 9-cis retinoic acid, known to affect the lipid metabolism through the retinoic X receptor.<sup>147</sup> The downregulation of apoM in liver caused by a LXR agonist was recently confirmed by Calayir *et al.*<sup>148</sup> They also

showed that apoA-I was downregulated in a similar manner. Surprisingly, an upregulation of apoM, apoA-I and ABCA1 was found in the small intestine as well as in Caco-2 cells.<sup>148</sup> The reason for the differential effects in liver and intestine is unknown but it is interesting that apoM behaves comparably to other main genes involved in reverse cholesterol transport in both tissues.

**Leptin**, a hormone secreted by adipose tissue, has been shown to influence the hepatic lipid and lipoprotein metabolism.<sup>149,150</sup> The apoM expression *in vivo* was increased by Leptin,<sup>150,151</sup> however, addition of supra-physiological leptin concentrations were shown to inhibit the apoM transcription in HepG2 cells.<sup>152</sup> Further investigations are needed to explain the contradictory effects of leptin *in vitro* and *in vivo*.

HepG2 cell cultures have been used extensively to study apoM expression and how it is affected by various factors. Two studies have investigated the effect of inflammatory parameters on apoM.<sup>142,143</sup> In the first study platelet-activating factor (PAF) significantly enhanced the apoM mRNA levels and the secretion in HepG2 cell cultures, an effect that the PAF-receptor antagonist, Lexipafant, significantly suppressed.<sup>143</sup> In the second study the four cytokines, transforming growth factor-alpha (TGF- $\alpha$ ), transforming growth factor-beta (TGF- $\beta$ ), epidermal growth factor and hepatic growth factor were able to decrease apoM expression levels, with TGF- $\beta$  being the most effective.<sup>142</sup>


### **The structure and ligand-binding abilities of apoM (Papers I-II)**

Knowledge of the three-dimensional structure of a protein is of major importance in providing insights into its molecular functions, as proteins with similar folds may have similar functions. Already in 1999, apoM was proposed to be a lipocalin. This hypothesis was based on sensitive sequence searches, threading and, later on, comparative model building.<sup>111,115</sup> As has been discussed in a previous chapter, lipocalins share a highly conserved fold, consisting of an eight-stranded antiparallel  $\beta$ -barrel, flanked by a  $\alpha$ -helix.<sup>83,84</sup> The lipocalin family also contains a highly conserved tryptophan

that points towards the inside of the hydrophobic pocket (Trp47 in apoM) (Fig 4). As previously shown for RBP, the highly conserved tryptophan was important for maintaining the stability of apoM and receiving high yields during the refolding process of recombinantly produced apoM.<sup>114,153</sup> ApoM contains, apart from the conserved tryptophan (Trp47), a second tryptophan at position 100 (Trp100) facing the hydrophobic pocket close to its opening (Fig 4). By using the fluorescence from the two tryptophans for intrinsic fluorescence quenching, the ligand binding abilities of apoM was studied.<sup>114</sup> Small lipophilic substances such as cholesterol, progesterone, arachidonic acid and vitamin K were tested. Binding of retinol and its two metabolites all-*trans*-retinoic acid and 9-*cis*-retinoic acid was detected with dissociation constants around 2-3  $\mu\text{mol/l}$  whereas the other ligands did not bind.<sup>114</sup> The intrinsic fluorescence of two apoM mutants, carrying single tryptophans, was quenched by retinol and retinoic acid to the same extent as wild-type apoM, indicating that the environment of both tryptophans was affected by the binding.<sup>114</sup> Plasma RBP binds retinoids with ten times higher affinity than the one estimated for apoM in this study. Moreover, RBP has a higher plasma concentration (3  $\mu\text{mol/l}$ ) than apoM (0.9  $\mu\text{mol/l}$ ), questioning the physiological importance of the detected retinoid binding.

ApoM was identified as an outlier lipocalin.<sup>98</sup> For outlier lipocalins, if not for all, the sequence diversity makes crystallization and structure solution the only certain way of determining their inclusion in the lipocalin family. Recently, we managed to determine the 1.95 Å resolution crystal structure of recombinant apoM expressed in *E. Coli* (Figure 4).<sup>153</sup> ApoM displays the typical lipocalin fold that was predicted, i.e. characterized by an 8-stranded antiparallel  $\beta$ -barrel enclosing an internal ligand-binding pocket, flanked by a  $\alpha$ -helix. The eight strands are linked by seven loops, the first being more extended and partially closing the internal ligand-binding pocket at one end. ApoM contains three disulfide bridges. Two of these covalently attach the extended N- and C-terminal tail segments to the lipocalin core fold. The ligand-binding pocket in apoM can be subdivided into a hydrophilic upper part, surrounded by several positively and negatively charged residues (Arg98, Arg143, Asp169 and Glu136), and a hydrophobic lower part

lined by numerous hydrophobic residues. An unexpected discovery was the binding of either myristic acid or glycerol-1-myristate in the hydrophobic pocket. Fatty acid and lipid binding studies, once again using intrinsic fluorescence quenching,



**Figure 4.** Overall structure of apoM. (A) Barrel-like fold in apoM showing the  $\beta$  strands (purple), helices (turquoise), loops (brown) and the N and C-termini. (B) The cocrystallized myristic acid is shown as a sphere model and coloured yellow and red. (C) The tryptophans are shown in red and myristic acid in green. (D) ApoM, as pictured in C, rotated by  $90^\circ$  around the horizontal axis.<sup>153</sup>

identified D-sphingosine ( $IC_{50}$  of 0.39  $\mu\text{mol/l}$ ) and sphingosine-1-phosphate ( $IC_{50}$  of 0.90  $\mu\text{mol/l}$ ) as two possible physiological ligand candidates.<sup>153</sup> D-sphingosine is phosphorylated by sphingosine kinase types 1 and 2, to form Sphingosine-1-phosphate.<sup>154</sup>

Sphingosine-1-phosphate is a signalling sphingolipid, but is also referred to as a bioactive lipid mediator.<sup>155</sup> Sphingosine-1-phosphate is mainly associated to HDL but its major source is haematopoietic cells (erythrocytes, platelets and leukocytes).<sup>156,157</sup> It may, according to several studies, account for many of the anti-atherogenic activities of HDL, including HDL acting as an immunomodulator and having anti-oxidant functions.<sup>155,157</sup> By considering the lipocalin family in general, and the specificity of the ligand-binding and binding of sphingosine-1-phosphate in particular, some speculation as to the physiological function can be made. The mechanisms governing translocation of sphingosine-1-phosphate from cells to the HDL particle is not known, neither is it known where in the HDL particle sphingosine-1-phosphate is located.<sup>157</sup> ApoM could be involved in the uptake and storage of sphingosine-1-phosphate in HDL and the protective effects seen by both apoM and sphingosine-1-phosphate might be connected.

The presence of myristic acid in the binding pocket made it difficult to estimate the affinity of the binding and also questions the dissociation constants estimated for the retinol binding. Both sphingosine-1-phosphate and D-sphingosine quenched the fluorescence of Trp100 specifically. The sphingosine-1-phosphate mediated quenching could be reversed by myristic acid and D-sphingosine whereas the fluorescence of Trp47 was unaffected.<sup>153</sup> This suggests that the strong quenching observed by addition of D-sphingosine and sphingosine-1-phosphate is caused by the exchange of myristic acid and the other ligand, and that they all bind with the hydrocarbon chain down in the pocket so that Trp47 remains unaffected.<sup>153</sup> Retinoic acid on the other hand quenches both tryptophans equally and does not compete with sphingosine-1-phosphate, questioning whether this substance binds into the same hydrophobic pocket.<sup>153</sup> However, the shifts in fluorescence we see can still be results from conformational changes of the  $\beta$ -barrel, making any conclusions about binding sites premature.




## The apoM signal peptide (Papers III-IV)

Most apolipoproteins have amphipathic motifs, a feature that is important when binding to the lipoprotein particles.<sup>158,159</sup> Amphipathic  $\beta$ -sheets, located throughout the apoB-100 molecule, alternating with amphipathic  $\alpha$ -helices have been proposed to explain how apoB-100 is oriented in the LDL particle.<sup>159-161</sup> The secondary structure of apoA-I has been extensively studied, with a lot of focus on its amphipathic  $\alpha$ -helices and its role in lipid-binding specificity.<sup>162,163</sup> ApoM on the other hand does not have any amphipathic motifs and no hydrophobic patches that can explain the binding to lipoproteins. However, apoM has an unusual feature, only shared by two other plasma proteins (paraoxonase-1 (PON-1) and haptoglobin related protein), apoM is circulating with a retained signal peptide.<sup>111,164,165</sup> The signal peptide was hypothesized to be responsible for the association between apoM and the lipoproteins. A signal peptide is a hydrophobic, 20-30 residues long amino acid chain.<sup>166</sup> Normally the signal peptide is cleaved by a type I signal peptidase when it has fulfilled its purpose of guiding the growing peptide chain into the endoplasmic reticulum.<sup>166,167</sup> The sequence homology of signal peptides is low but they share some common features; basic at the N-terminus, apolar in the middle and small uncharged amino acid residues preceding the site of cleavage by the signal peptidase.<sup>168,169</sup> For the signal peptidase cleavage the amino acids on position -3 and -1 from the cleavage site are crucial.<sup>169</sup> By a single amino acid change from a glutamine to an alanine at position 22 (Q22A), which is position -1 from the predicted cleavage site, a cleavage site was successfully inserted in apoM.<sup>166</sup> By expressing both wild-type apoM and apoM<sup>Q22A</sup> in human embryonic kidney 293 (HEK293) cells it could be shown that while wild-type apoM was incorporated into particles of the same size as lipoproteins, apoM<sup>Q22A</sup> was secreted from the cells as free protein.<sup>166,170</sup> In plasma from mice injected with either human wild-type apoM or apoM<sup>Q22A</sup>, wild-type apoM was recovered from the lipoprotein fraction, whereas apoM<sup>Q22A</sup> was found in the lipoprotein-free fraction (Fig. 5).<sup>171</sup> However, apoM<sup>Q22A</sup> was not detectable in plasma from transgenic mice expressing apoM<sup>Q22A</sup> unless the kidney arteries were ligated

while wild-type apoM was easily detected. Thus the signal peptide is not only crucial for lipoprotein association but also for keeping apoM in circulation and preventing rapid loss by filtration in the kidneys (Figure 5).<sup>171</sup>

In an attempt to investigate the mechanisms governing apoM secretion, HepG2 and stably transfected HEK293 cells, expressing wild-type apoM or apoM<sup>Q22A</sup>, were cultured. While endogenously expressed apoM from HepG2 cells cultured under serum-free conditions was incorporated into lipoprotein-like particles, wild-type apoM expression from HEK293 cells



**Figure 5.** Wild-type apoM is synthesized in the liver and associates with HDL, but also other lipoprotein classes, in the circulation. ApoM<sup>Q22A</sup> is circulating as a free protein and, due to its small size, is rapidly cleared in the kidney. Reproduced from Future Lipidology (2008) 3(5), 495-503 with permission of Future Medicine Ltd.

dropped dramatically.<sup>170</sup> In contrast, when cultured in medium containing serum wild-type apoM was well expressed and incorporated in lipoprotein particles similar to those formed from HepG2 cells. ApoM<sup>Q22A</sup> was readily expressed as a free protein from HEK293 cells both in serum-free and serum containing conditions. By measuring apoM mRNA and protein levels in cell lysates it was found that wild-type apoM accumulated in the HEK293 cells when cultured under serum-free conditions indicating that a vector in serum is needed for proper apoM secretion. Results suggested that lipoproteins might be involved in the secretion of apoM and addition of HDL, but not LDL, to the culture media completely restored wild-type apoM expression.<sup>170</sup> As HEK293 cells do not produce any apolipoproteins or cholesterol transporters such as ABCA-1, ABCG-1 or SR-B1 this suggests that addition of HDL to the culture media is just as efficient in stimulating apoM secretion as coexpression of lipoprotein particles.

### **The apoM particle**

ApoM is mainly HDL associated but can still be found associated to lipoproteins of the other classes as well.<sup>111,164,165</sup> Christoffersen *et al.* isolated apoM-containing lipoproteins from plasma and showed that apoM is present in about 5% of the total HDL population and 2% of LDL.<sup>117</sup> It was also concluded that apoM appears to designate the apoM-containing population of HDL and LDL to be more antiatherogenic and less pro-atherogenic than HDL and LDL populations, respectively, as whole.<sup>117</sup> As described in a previous chapter, the HDL particles are very heterogeneous in size as well as in molecular weight and chemical composition. Wolfrum *et al.* detected apoM in pre $\beta$ -HDL as well as in  $\alpha$ -migrating HDL in both human and mouse serum.<sup>119</sup> In contrast, Christoffersen *et al.* were not able to detect any apoM in pre $\beta$ -HDL while it was readily detected in 8-12 nm large particles ( $\alpha$ -migrating).<sup>116</sup> Using isopycnic density gradient ultracentrifugation and liquid chromatography/electrospray mass spectrometry, apoM was found to be enriched in dense HDL<sub>3</sub> particles.<sup>172,173</sup> HDL<sub>3c</sub> particles, a subgroup of HDL<sub>3</sub>, are more potent than HDL<sub>2</sub>

in attenuating the LDL oxidation. The potent antioxidative effect of HDL<sub>3c</sub> particles was highly correlated to apoM levels as well as to SAA levels and PON-1 levels.<sup>173</sup> As HDL<sub>3</sub> also carries the highest amount of Sphingosine-1-phosphate (40-50 mmol Sphingosine-1-phosphate/mol HDL<sub>3</sub>) making the binding of S1P to apoM even more intriguing.<sup>174</sup>

Glycosylations are common post-translational modifications of proteins, known to affect their properties and functions. Human apoM is partially glycosylated (~80%) in the circulation and Asn135 has been identified as the glycosylation site.<sup>111,115,164,175-177</sup> In total five different isoforms of apoM in LDL and HDL have been identified; three are both N-glycosylated and sialylated, one is N-glycosylated but not sialylated and one is neither glycosylated nor sialylated. The individual physiological roles of these isoforms, if any, have not been elucidated.<sup>177</sup>

### **ApoM in the kidney**

The two membrane receptors megalin and cubulin are highly expressed in the endocytic pathway of the renal proximal tubule.<sup>178,179</sup> Both receptors are important for normal reabsorption of proteins in the proximal tubule.<sup>179</sup> Megalin has been shown to bind lipocalins (RBP and alpha-1-microglobulin) apolipoprotein H, albumin, transthyretin amongst others, whereas identified ligands for cubulin include transferrin, immunoglobulin light chains and apoA-I.<sup>178,180-182</sup> However, one of the most important functions of these receptors is to rescue protein-bound components, such as microelements and vitamins i.e. vitamin A, B<sub>12</sub> and D.<sup>181</sup> ApoM is expressed in liver and in tubular epithelial cells in the kidney.<sup>111,113</sup> There are several hypotheses regarding the function of apoM expressed in the liver but the function of kidney derived apoM is far from obvious. The high apoM expression in the proximal compared to the distal tubules, and its absence in Henle's loop, may suggest a specific function.<sup>113</sup> Megalin was shown to be a receptor for apoM and mediated its uptake in the kidney tubule cells.<sup>183</sup> ApoM was secreted in the urine of megalin deficient mice, while apoM was detected neither in wild-type mouse nor in human urine.<sup>183</sup> These results suggest that the megalin-

mediated endocytosis in kidney proximal tubules prevents apoM excretion in the urine.

### **ApoM in mice**

The amino acid sequences of human and mouse apoM are 79% identical.<sup>120,125</sup> As in humans, mouse apoM is expressed in hepatocytes and in kidney proximal tubule cells.<sup>125</sup> Mouse apoM is also secreted with a retained signal peptide, but unlike human apoM it is not glycosylated.<sup>125</sup> ApoM levels in mouse plasma are decreased in apoA-I deficient mice, which suggests a connection between apoM and apoA-I metabolism.<sup>125</sup> Several studies have suggested that apoM is important for pre $\beta$ -HDL formation and cholesterol efflux *in vivo* in mice and thereby inhibits formation of atherosclerotic lesions.<sup>116,119</sup> Christoffersen *et al.* showed that apoM increased the LCAT-independent generation of pre $\beta$ -HDL in plasma.<sup>116</sup> Pre $\beta$ -HDL particles are considered the initial extracellular acceptors of cellular cholesterol upon efflux from peripheral tissues. According to one study pre $\beta$ -HDL formation was impaired in apoM deficient mice resulting in cholesterol accumulation in large HDL particles (HDL<sub>1</sub>). This dramatic effect was observed in both HNF-1 $\alpha$  deficient mice and in wild-type mice treated with siRNA directed against apoM, but was not seen in another study of apoM<sup>-/-</sup> mice.<sup>116,119</sup> However, in both studies mice overexpressing apoM developed smaller atherosclerotic lesions compared to controls.<sup>116,119</sup> The connection between apoM and pre $\beta$ -HDL formation was later confirmed in humans where apoM plasma levels were positively associated with both pre $\beta$ -HDL levels and pre $\beta$ -HDL formation.<sup>184</sup>

The affect of acute phase response on apoM has also been studied in mice. ApoM mRNA levels were shown to be decreased in liver and kidney of mice treated with lipopolysaccharide (LPS), zymosan or turpentine. Moreover, treatment with TNF- $\alpha$  or interleukin-1 decreased apoM expression in Hep3B cell cultures.<sup>118</sup> In a mouse model of hepatic ischemia-reperfusion injury (IRI) apoM mRNA levels were decreased during the first 3 hours, indicating that they were significantly influenced by the acute-phase of IRI.<sup>185</sup>

## **ApoM in humans**

Several interesting findings on apoM *in vitro* and in mice have been found. Unfortunately, not many of these have so far been able to be translated into the situation in humans. To be able to study apoM plasma levels in humans and how these are affected by different diseases we developed an apoM ELISA.<sup>186</sup> The mean apoM plasma level in a population of healthy volunteers was around 0.9  $\mu\text{mol/l}$  corresponding to 23 mg/l, i.e. a lot less than the protein most abundant in HDL, apoA-I.<sup>186</sup> Using this ELISA we could establish reference values for healthy individuals; 0.58-1.18  $\mu\text{mol/l}$  for women 18-49 years old and 0.61-1.30  $\mu\text{mol/l}$  for women 50+ years and for men.<sup>186</sup> A positive correlation was observed for apoM levels and age among women.<sup>186</sup> The reason for the correlation is unknown but speculations around hormonal effects on apoM expression or elimination is tempting. Somewhat unexpectedly, a strong correlation between apoM and total cholesterol levels was revealed in the same healthy individuals ( $r=0.52$ ) as well as HDL and LDL cholesterol levels.<sup>186</sup> This relationship has since been found in other populations.<sup>82,187</sup> One group has reported increased plasma apoM levels in hepatocellular carcinoma, liver cirrhosis and chronic hepatitis.<sup>188</sup> The method used to measure apoM levels was semi-quantitative and the study population was small so it may be too early to draw firm conclusions about the apoM levels in these liver diseases.

## **ApoM in diabetes**

There have been many studies in both mice and humans suggesting that apoM regulation may be linked to glucose and lipid metabolism. Decreased plasma apoM levels have been found in several mouse models of type 2 diabetes.<sup>151,189</sup> In contrast to the results seen in mice, apoM gene expression in cultured liver cells was downregulated by insulin,<sup>190,191</sup> and in a recently published paper, apoM plasma levels were ~9% lower in patients with type 2 diabetes compared to controls.<sup>184</sup> In 2007, a study of three single-nucleotide polymorphisms (SNPs) in apoM, C-1065A, T-855C and T-778C, found that the SNP T-778C was associated with increased levels of plasma total cholesterol

and fasting plasma glucose and conferred the risk of development of type 2 diabetes.<sup>192</sup>

MODY is a group of six different monogenic forms of diabetes characterized by autosomal dominant inheritance, onset before 25 years of age, and pancreatic  $\beta$ -cell dysfunction.<sup>122,193</sup> MODY3 is caused by mutations in the gene encoding HNF-1 $\alpha$ .<sup>122</sup> It is characterized by a severe insulin secretion defect in response to glucose.<sup>122</sup> HNF-1 $\alpha$  regulates apoM gene expression in mice, as discussed in a previous chapter.<sup>124</sup> In 2003, Richter *et al.* found that MODY3 patients had a ~36% reduction in apoM levels compared to control subjects, whereas MODY1 patients had normal plasma apoM levels.<sup>124</sup> The authors suggested that apoM levels might be a useful serum marker for the identification of MODY3 patients. More recently however, apoM levels were assessed in two other populations. In none of these studies any difference in the plasma apoM levels were detected between either MODY3 patients and controls or between MODY3 patients and patients with type 2 diabetes.<sup>126,127</sup>

Metabolic syndrome is a heterogeneous disease that associates abdominal obesity and several metabolic factors with elevated blood pressure levels.<sup>194,195</sup> It is associated with increased risk of CVD and diabetes. The main physiological processes underlying metabolic syndrome are insulin resistance and inflammation.<sup>194-196</sup> Dullaart *et al.* showed that plasma apoM was on average 15% lower in subjects with metabolic syndrome compared to controls in a Dutch population. Furthermore, apoM correlated inversely to body mass index (BMI) and waist circumference. However, apoM was not correlated to any of the diabetic parameters such as glucose, insulin, leptin or the intermedia thickness.<sup>197</sup> The lack of correlation between apoM levels and leptin is particularly interesting as it is conflicting with previously published studies where a positive association between apoM and leptin levels was found.<sup>150,151,198</sup>

### **ApoM in cardiovascular diseases (Paper V)**

CHD is the leading cause of death in all ages.<sup>20</sup> CHD is a narrowing of the coronary arteries caused by atherosclerosis resulting in stable angina pectoris or MI. As described in the

section about apoM and diabetes three SNPs in the apoM gene have been described.<sup>192</sup> A case-control study showed that SNP T-778C and T-855C alleles were associated with CHD.<sup>199,200</sup> Since apoM correlates strongly to total cholesterol levels and there is a well-established relationship between total plasma cholesterol and CHD and MI<sup>23,201,202</sup> we investigated whether there is a relationship between serum apoM levels and the risk for CHD.<sup>82</sup> We measured the apoM levels in two separate populations, based on FINRISK '92<sup>203,204</sup> and CCHS.<sup>205,206</sup> There was no significant difference in mean apoM levels between cases developing CHD during follow up (10 years in FINRISK '92 and 23 years for CCHS) and controls. Also, in conditional logistic regression analyses, apoM was not a predictor for CHD events.<sup>82</sup> Recently another study was published, reporting a slight increase in plasma apoM levels in CHD patients.<sup>207</sup> The difference between this study and the previous ones is that they measured apoM levels in present disease, whereas the other two described the apoM levels at baseline before the disease was developed. Since the apoM levels in the latter study was measured by a method that is at best semi-quantitative (semi-quantitative dot blot technique) it is still too early to draw firm conclusions about apoM levels in established CHD.<sup>207</sup>



## FUTURE PERSPECTIVES

The long-term goal is to elucidate the physiological function of apoM and its involvement in disease. In order to get there we have a lot of loose ends to start working with.

One important tool that we have available now that we did not have before is the 3D structure of apoM. Thus, we know for certain that apoM is a lipocalin and the search for ligands with physiological functions does now seem even more relevant. As apoM was crystallized in complex with myristic acid we know that apoM binds fatty acids. Albumin, the major transporter of fatty acids,<sup>208</sup> is present at almost 1000-times higher concentration in plasma than apoM which makes it difficult to envision a biological role for apoM as a fatty acid binding protein. The binding of D-sphingosine and sphingosine-1-phosphate is more intriguing, especially as apoM and sphingosine-1-phosphate are present in the same HDL subpopulation. Since both apoM and sphingosine-1-phosphate have been suggested to be anti-atherogenic it is of course of interest to see how these effects are connected.

Another interesting question for the future is the details on apoM secretion. As the hydrophobic signal peptide is retained, the phospholipids-bound apoM needs to be transferred from the phospholipids layer of the cell membrane to the phospholipids on the lipoprotein. A docking process during which an undefined acceptor complex becomes transiently associated with the cell membrane has been hypothesized to be involved in the release of PON-1.<sup>209</sup> Whether a similar mechanism is conceivable for apoM or not would be interesting to elucidate.

A strong association between apoM and cholesterol has been shown in several studies, but the mechanism behind this association remains unknown. Various groups are currently trying to unravel whether the answer lies at the gene regulation level, caused by transcription factors, or at the protein level in the lipid metabolism. The involvement of apoM in inflammation and acute-phase response has also been discussed, but more extensive studies are needed. SAA, an acute phase reactant, has been shown to displace apoA-I from HDL.<sup>210-212</sup> Also, acute-phase HDL is more rapidly cleared from the circulation during inflammation, myocardial infarction or ischemia than what is observed for normal HDL that has apoA-I as the major apolipoprotein moiety.<sup>211</sup> What the functional connections between inflammation and apoM levels are is not known, but since apoM levels were unaffected in subjects that later developed CHD it seems likely that the disease in itself causes the decrease in apoM levels. However, to fully understand the role of apoM in atherosclerosis and other diseases it could be of interest to use the apoM ELISA to measure apoM levels in a variety of inflammatory diseases. Also, the availability of genetically modified mice, both apoM-knockout mice and apoM-transgenic mice is an important tool when investigating the molecular mechanisms of its involvement in disease processes.

## POPULAR SCIENTIFIC SUMMARY

Fat is one of the most important energy sources for humans, but to be able to use the energy it has to be transported to the organs where it's needed. To do this our body forms particles that are called lipoproteins. Lipoproteins are round particles with water-soluble molecules on the surface surrounding a core of fat. The particles mainly contain fat, cholesterol and proteins (apolipoproteins). It's the apolipoproteins that decide where the lipoproteins will go. The particles are divided into different groups either dependent on their density, electric charge or dependent on which proteins they contain. LDL (low-density lipoproteins) and HDL (high-density lipoproteins) are the most common classes. They are often called "bad" and "good" cholesterol, respectively, because research has shown that much LDL increases a person's risk of getting cardiovascular diseases (diseases in the heart and the blood vessels) while HDL has the opposite effect. Some of the apolipoproteins are limited to only one or a few of the lipoprotein classes while other are present in all. Apolipoprotein A-I (apoA-I) is the main protein in HDL while apolipoprotein B (apoB) is the main one in LDL. Newly discovered apolipoproteins are typically simply named with the next letter of the alphabet.

Apolipoprotein M (apoM) is mainly present in HDL, but it can be found in all other lipoprotein classes as well. The liver and kidneys produce apoM and then let it out in the blood. What apoM is good for is not known today. We know which chromosome that contains the apoM gene, and it has been

possible to follow apoM far back in evolution. Many different species have apoM, including most mammals and fish. Using different data base searches and modelling apoM was predicted to be a lipocalin, even though it was not known exactly what the protein looked like.

The lipocalins are a large family of proteins, which all look fairly similar. They form a pocket where small, fat-soluble molecules can bind. Many lipocalins transport molecules such as vitamins, cholesterol and fat. Retinol binding protein is an example of a lipocalin that is a known transporter, it transports vitamin A in the blood. However, there are a lot of other lipocalins where we don't know their function.

Through binding experiments we managed to show that apoM binds vitamin A (paper I). We don't know if this binding has any physiological function or not, but it shows that apoM binds small fat-soluble molecules and by that behaves like a lipocalin. We have recently also been able to determine the 3D structure of apoM, i.e. determine exactly what it looks like and can thereby show that it is indeed a lipocalin (paper II). It might not sound very exciting, but by knowing what the protein looks like we can get important clues that can help us figure out what it does. When we determined the structure we could also see that a particular fatty acid, called myristic acid, was bound in the pocket of apoM. We have also shown that apoM binds two molecules that are believed to add to the good effects of HDL (D-sphingosine and sphingosine-1-phosphate).

All proteins are produced inside cells. When they are produced they have a short stretch of amino-acids (the building blocks of proteins) that works much like an address-tag, which guides the protein to the right places inside the cell. For proteins that are exported to the blood, this address-tag is normally cut off at an early stage. In apoM it remains part of the finished protein, something that is very uncommon among proteins. We have been able to show that this tag is necessary for apoM to be able to bind to the lipoprotein particles (paper III). Without it, apoM would be circulating as a free protein and be so small that it would be filtered through the kidneys and be lost in the urine. However, the amino acid-tail also makes it a lot trickier for apoM to get out from the cells and reach the blood. We managed to show that some kind of "acceptor" is needed for

apoM to get out from the cells and that HDL, in contrast to LDL, may be that acceptor (paper IV).

Work in mice has shown that apoM protects against an inflammation of the arteries with build up of fat that can lead to heart attack, stroke or angina etc. One of the causes of these diseases is high cholesterol level in the blood. We have seen in humans that if you have high levels of apoM in blood you often have high levels of cholesterol and vice versa. This made it interesting to see if the apoM level in a blood sample, taken many years earlier, could predict who would later get heart attack and not. We compared a group of people who later had a heart attack with a similar group who didn't in both a Danish and a Finnish study (paper V). The apoM levels were the same. Another group of scientists have shown that people who had already had a heart attack had slightly more apoM in their blood than healthy volunteers. Perhaps the amount of apoM in the blood is affected by the disease but doesn't have anything to do with getting the disease. More research is needed to answer this question.

## POPULÄRVETENSKAPLIG SAMMANFATTNING

Fett är en av människans viktigaste energikällor. För att kunna utnyttja energin måste den kunna transporteras i blodet dit där den behövs. För att kunna göra detta bildar vår kropp partiklar som kallas för lipoproteiner. Dessa är runda partiklar som har en yta uppbyggd av vattenlösliga molekyler som omsluter en fet kärna. Partiklarna innehåller framför allt fett, kolesterol och proteiner (apolipoproteiner). Det är apolipoproteiner som håller ihop lipoproteiner och som styr vart de tar vägen. Partiklarna delas upp i olika grupper, antingen beroende på densitet, elektrisk laddning eller beroende på vilka proteiner de innehåller. LDL (low-density lipoproteins) och HDL (high-density lipoproteins) är de vanligaste typerna och kallas ofta för det onda respektive det goda kolesterolet. Detta beror på att höga koncentrationer av LDL i blodet ökar risken för hjärt-kärlsjukdomar, medan HDL minskar risken för de samma. Vissa apolipoproteiner finns bara i en eller några lipoproteintyper medan andra finns i samtliga. Apolipoprotein A-I (apoA-I) är det protein som det finns mest av i HDL, medan apolipoprotein B (apoB) är vanligast i LDL.

Apolipoprotein M (apoM) är ett apolipoprotein som framför allt finns i HDL, men det finns också i mindre mängder i de andra lipoproteintyperna. ApoM tillverkas i levern och i njurarna. Man vet vilken kromosom apoM genen finns i och man har kunnat följa apoM långt bak i evolutionen. Många djurarter har apoM, både däggdjur och fiskar, men exakt vad apoM är till för vet man inte. Man har med hjälp av att söka i

olika databaser och med datormodelleringar sett att apoM förmodligen är en lipokalin.

Lipokaliner är en stor proteinfamilj som alla ser ungefär likadana ut. De ser ut som en ficka som små, fettlösliga molekyler kan binda, såsom vitaminer, kolesterol och fett. Retinolbindande protein är ett expempel på en lipokalin som är en känd transportör, vilken transporterar vitamin A i blodet. Det är dock inte många lipokaliner som man vet vad de är till för.

Vi lyckades med hjälp av bindningsexperiment visa att apoM binder vitamin A (artikel I). Om denna bindning har någon fysiologisk betydelse vet vi inte, men det visar att apoM, precis som de flesta lipokaliner, kan binda små fettlösliga molekyler. Vi har nu också lyckats fastställa hur apoM ser ut genom att göra kristaller av proteinet och faktiskt visa att det är ett lipokalin (artikel II). Det kanske inte låter så intressant, men när man vet hur ett protein ser ut kan man få reda på ganska mycket om dess funktion. När vi fastställde hur apoM ser ut såg vi att en fettsyra som heter myristinsyra redan fanns bunden till apoM. Förutom att binda fettsyror har vi också sett att apoM kan binda D-sfingosin och sfingosin-1-fosfat. Dessa två molekyler tror man bidrar till den skyddande effekt som man ser hos HDL mot hjärt-kärlsjukdomar.

Alla proteiner tillverkas inuti cellerna. När proteiner produceras har de en liten svans av aminosyror, en signalpeptid, som fungerar som en adresslapp som guidar proteinet till rätt platser i cellen. Denna klipps normalt sett av innan proteinet kommer ut i blodet. Det gör den dock inte i apoM och vi har lyckats visa att signalpeptiden är nödvändig för att apoM ska kunna binda till lipoproteiner (artikel III). Om denna hade klippts av hade apoM cirkulerat fritt i blodet och varit så pass litet att det filtrerats bort i njuren och försvunnit ut i urinen. Signalpeptiden gör det svårt för apoM att komma ut ur cellen till blodet. ApoM behöver en partikel som tar emot apoM på utsidan av cellen och vi har visat att HDL kan fungera som en sådan medan LDL inte gör det (artikel IV).

I möss har man sett att apoM skyddar mot åderförkalkning, förstadiet till hjärtinfarkt, stroke, kärlkramp etc. Vi har också sett att om människor har mycket apoM i blodet har de ofta höga kolesterolnivåer och vice versa. Eftersom det är känt att höga kolesterolnivåer ökar risken för hjärtinfarkt ville vi se om apoM

nivåerna säger något om vilka som senare får hjärtinfarkt och inte (artikel V). ApoM nivåerna visade sig vara desamma hos dem som senare fick hjärtinfarkt och dem som förblev friska. Det är dock en annan grupp som har sett en liten ökning i apoM nivån i blodet hos patienter med hjärt-kärlsjukdom jämfört med friska frivilliga. Det kan vara så att apoM nivån påverkas av själva sjukdomen men inte har något med själva sjukdomsutvecklingen att göra. Detta är dock något som behöver utredas vidare.



## ACKNOWLEDGEMENTS

**Björn**, tack för att jag fick göra min forskarutbildning i din grupp. Du har varit en bra och engagerad handledare, jag har lärt mig massor och ditt genuina intresse för forskning har varit mycket inspirerande. **Olof**, tack för alla trevliga diskussioner, både om apoM och alla andra möjliga ämnen, det har varit ett nöje! **Lars Bo**, **Christina** och **Sara**, tack för all värdefull input. Vårt samarbete och våra diskussioner har varit otroligt givande! A big thank you to all coauthors, I would in particular like to acknowledge Prof **Yves Muller**, Dr **Madhumati Sevvana** and Mrs **Claudia Egerer-Sieber** for the excellent work with the apoM structure. Ett stort tack till mina kära studenter, **Anna**, **Emelie**, **Caroline**, **Staffan** och **Helena**, för all hjälp.

**Propisoff**, tack för allt stöd både på labbet och utanför och tack för att du orkar med mig när jag nojjar. **Calle**, hyssmärstaren, löparpolaren och labbets buffert. De här fyra åren hade inte alls varit lika roliga och spännande utan dig! **Cecilia**, det var trevligt att få lite sällskap bland "apos" och ute i "skrubben". Tack för att du alltid hjälper till, ger tips och råd, och alltid engagerar dig. **Anna**, tack för att du fick mig att känna mig så välkommen när jag kom och för alla roliga stunder vi har haft med dans, sång, konstiga sumofilmer och Balder. **Sinh**, det var trevligt att få vara din skrivbordsgranne. Tack för alla trevliga stunder både i och utanför labbet. **Li**, tack för all värdefull hjälp! Oavsett hur mycket du har att göra så hjälper du till, och alltid med ett leende på läpparna. **Eva**, du var ett värdefullt tillkott till labbet, både forskningsmässigt och socialt. Hör av dig om din blivande man kommer tillbaka till Köpenhamn! **Lina**, tack för du alltid lyssnar och bryr dig. **Mike**,

thanks for all nice chats, both about science and more “important” stuff. **Sara Italiano**, it’s been great to have you in the lab. Thanks for all the laughs. **Jun**, it was nice to get to know you. I hope you’ll enjoy your time in the lab just as much as I have. **Slottsdelägare Hansvik**, tack för att du alltid har samma tålamod när jag panikringer för att någonting har gått sönder. **Eva-Lotta**, tack för att du alltid tar dig tid att hjälpa till med allt krångligt pappersarbete som en labråtta inte reder ut.

A big thank you to all coworkers at **floor 4 and 5** at the Wallenberg lab for the nice atmosphere, both socially and scientifically.

**Jennie** och **Andreas**, min “andra familj”. Tack för att ni alltid finns där! **Micke**, tack för att du alltid tror på mig och tjatade på mig så att jag började doktorera från första början. Det hade inte blivit någon avhandling utan dig. **Sara**, tack för att du är den raka, ärliga, glada person som du är. Jag har saknat att sitta i fönstret på 4:an och snacka “forskning”. **Lotta**, min vän, tack för alla kvällar med rödvin och skvaller, det bästa sättet att glömma misslyckade experiment allmänt kassa dagar.

**Mamma & Pappa, Ulrika & Pierre, Henrik & Madeleine**, min kära familj, för allt ert stöd och outtömliga tålamod och för att ni har stått ut med mitt förvirrade jag under de här åren. **Vilma, Elsa** och **lilla trollet**, mina solstrålar som förgyller vilken dag som helst.

My **Angus**, thanks for being the stable, relaxed person that you are. You always remind me of what’s really important in life.

*Projektet finansierades genom bidrag från Vetenskapsrådet, ALF-medel, Knut och Alice Wallenbergs stiftelse, Hjärt-Lungfonden, Söderbergs stiftelse och Medicinska Fakultetens doktorandmånader. Resestipendier erhöles från Apotekarsocieteten, Kungliga Fysiografiska sällskapet och Medicinska Fakultetens resestipendier.*

## BIBLIOGRAPHY

1. Nilsson-Ehle P. Energiomsättning. In: Nilsson-Ehle P, ed. *Laurells klinisk kemi i praktisk medicin*: Studentlitteratur; 2003.
2. Berg JM, Tymoczko JL, Stryer L. The Biosynthesis of Membrane Lipids and Steroids *Biochemistry*: W.H. Freeman and Company New York; 2002.
3. Scanu AM, Edelstein C, Keim P. Serum Lipoproteins. In: Putnam FW, ed. *The Plasma Proteins*: Academic Press; 1975.
4. Beisiegel U. Lipoprotein metabolism. *Eur Heart J*. 1998;19 Suppl A:A20-23.
5. Beisiegel U. Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism. *Curr Opin Lipidol*. 1995;6:117-122.
6. Gornic H, Plutzky J. *Atlas of Heart Diseases: Cardiovascular Risk Factors*. Current Medicine Group LLC.; 2006.
7. Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. *Faseb J*. 2008;22:4044-4054.
8. Barter PJ, Rye KA. *Hight Density Cholesterol: The New Target. A Handbook for Clinicians*. . Birmingham: Sherbone Gibbs Limited; 2005.
9. Curtiss LK, Valenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse cholesterol transport? *Arterioscler Thromb Vasc Biol*. 2006;26:12-19.

10. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. *Arterioscler Thromb Vasc Biol.* 2004;24:421-428.
11. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. *Arterioscler Thromb Vasc Biol.* 2001;21:13-27.
12. van der Velde AE, Groen AK. Shifting gears: liver SR-BI drives reverse cholesterol transport in macrophages. *J Clin Invest.* 2005;115:2699-2701.
13. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. *J Clin Invest.* 2005;115:2870-2874.
14. Kuvin JT, Alsheikh-Ali AA, Karas RH. High-density lipoprotein cholesterol-raising strategies. *J Cardiovasc Pharmacol.* 2006;47:196-204.
15. Krimbou L, Marcil M, Genest J. New insights into the biogenesis of human high-density lipoproteins. *Curr Opin Lipidol.* 2006;17:258-267.
16. Brewer HB, Jr. *Atlas of Heart Diseases: Atherosclerosis.* Current Medicine Group LLC; 2005.
17. Kunitake ST, La Sala KJ, Kane JP. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. *J Lipid Res.* 1985;26:549-555.
18. Lund-Katz S, Liu L, Thuahnai ST, Phillips MC. High density lipoprotein structure. *Front Biosci.* 2003;8:d1044-1054.
19. Yokoyama S. Assembly of high-density lipoprotein. *Arterioscler Thromb Vasc Biol.* 2006;26:20-27.
20. WHO. The Global Burden of Disease, 2004 Update. 2008.
21. Skalen K, Gustafsson M, Rydberg EK, Hultén LM, Wiklund O, Innerarity TL, Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. *Nature.* 2002;417:750-754.
22. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. *Arterioscler Thromb Vasc Biol.* 1997;17:107-113.

23. Mensah GA, Brown DW, Croft JB, Greenlund KJ. Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II). *Am J Prev Med.* 2005;29:68-74.
24. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterol. *Am J Cardiol.* 1980;46:649-654.
25. Sacks FM. The apolipoprotein story. *Atheroscler Suppl.* 2006;7:23-27.
26. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am J Med.* 1977;62:707-714.
27. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. *Am J Cardiol.* 2000;86:19L-22L.
28. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Jr., Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. *Circulation.* 1989;79:8-15.
29. Olofsson SO, Wiklund O, Boren J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. *Vasc Health Risk Manag.* 2007;3:491-502.
30. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med.* 2005;352:1685-1695.
31. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. *Annu Rev Pathol.* 2006; 1:297-329.
32. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. *Curr Opin Lipidol.* 2003; 14:421-430.
33. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-

- prone sites on the endothelium in the ApoE-deficient mouse. *Arterioscler Thromb Vasc Biol.* 1998;18:842-851.
34. Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. *Curr Vasc Pharmacol.* 2009;7:234-243.
  35. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. *Annu Rev Med.* 2003;54:321-341.
  36. Silver DL, Jiang XC, Arai T, Bruce C, Tall AR. Receptors and lipid transfer proteins in HDL metabolism. *Ann N Y Acad Sci.* 2000;902:103-111; discussion 111-102.
  37. Stein O, Stein Y. Atheroprotective mechanisms of HDL. *Atherosclerosis.* 1999;144:285-301.
  38. Oram JF, Vaughan AM. ATP-Binding cassette cholesterol transporters and cardiovascular disease. *Circ Res.* 2006;99:1031-1043.
  39. Assmann G, Gotto AM, Jr. HDL cholesterol and protective factors in atherosclerosis. *Circulation.* 2004;109:III8-14.
  40. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. *Circ Res.* 2004;95:764-772.
  41. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. *J Clin Invest.* 2007;117:746-756.
  42. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC. Proteomic analysis of high-density lipoprotein. *Proteomics.* 2006;6:721-730.
  43. Shiomi M, Fan J. Unstable coronary plaques and cardiac events in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits: questions and quandaries. *Curr Opin Lipidol.* 2008;19:631-636.
  44. Narayanaswami V, Ryan RO. Molecular basis of exchangeable apolipoprotein function. *Biochim Biophys Acta.* 2000;1483:15-36.
  45. Weisgraber KH. Apolipoprotein E: structure-function relationships. *Adv Protein Chem.* 1994;45:249-302.

46. Gangabadage CS, Zdunek J, Tessari M, Nilsson S, Olivecrona G, Wijmenga SS. Structure and dynamics of human apolipoprotein CIII. *J Biol Chem.* 2008;283:17416-17427.
47. Pownall HJ, Ehnholm C. The unique role of apolipoprotein A-I in HDL remodeling and metabolism. *Curr Opin Lipidol.* 2006;17:209-213.
48. Morrisett JD, Jackson RL, Gotto AM, Jr. Lipid-protein interactions in the plasma lipoproteins. *Biochim Biophys Acta.* 1977;472:93-133.
49. Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. *J Intern Med.* 2005;258:395-410.
50. Kim E, Young SG. Genetically modified mice for the study of apolipoprotein B. *J Lipid Res.* 1998;39:703-723.
51. Chan L, Chang BH, Liao W, Oka K, Lau PP. Apolipoprotein B: from editosome to proteasome. *Recent Prog Horm Res.* 2000;55:93-125; discussion 126.
52. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. *Arterioscler Thromb Vasc Biol.* 1995;15:963-971.
53. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. *Arterioscler Thromb Vasc Biol.* 1999;19:472-484.
54. Nestel PJ, Fidge NH. Apoprotein C metabolism in man. *Adv Lipid Res.* 1982;19:55-83.
55. de Haan W, Out R, Berbee JF, van der Hoogt CC, van Dijk KW, van Berkel TJ, Romijn JA, Jukema JW, Havekes LM, Rensen PC. Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo. *Biochem Biophys Res Commun.* 2008;377:1294-1298.
56. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. *Curr Opin Lipidol.* 2001;12:297-304.
57. Binger KJ, Pham CL, Wilson LM, Bailey MF, Lawrence LJ, Schuck P, Howlett GJ. Apolipoprotein C-II amyloid fibrils

- assemble via a reversible pathway that includes fibril breaking and rejoining. *J Mol Biol.* 2008;376:1116-1129.
58. Cho KH. Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL. *Mol Cells.* 2009;27:291-297.
  59. Wang CS. Structure and functional properties of apolipoprotein C-II. *Prog Lipid Res.* 1991;30:253-258.
  60. Ginsberg HN, Jones J, Blaner WS, Thomas A, Karmally W, Fields L, Blood D, Begg MD. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. *Arterioscler Thromb Vasc Biol.* 1995;15:1829-1838.
  61. Rassart E, Bedirian A, Do Carmo S, Guinard O, Sirois J, Terrisse L, Milne R. Apolipoprotein D. *Biochim Biophys Acta.* 2000;1482:185-198.
  62. Weech PK, Provost P, Tremblay NM, Camato RN, Milne RW, Marcel YL, Rassart E. Apolipoprotein D--an atypical apolipoprotein. *Prog Lipid Res.* 1991;30:259-266.
  63. Yang CY, Gu ZW, Blanco-Vaca F, Gaskell SJ, Yang M, Massey JB, Gotto AM, Jr., Pownall HJ. Structure of human apolipoprotein D: locations of the intermolecular and intramolecular disulfide links. *Biochemistry.* 1994;33:12451-12455.
  64. Terrisse L, Marcoux K, Carmo SD, Brissette L, Milne R, Rassart E. Structure-function relationships of human apolipoprotein D an immunochemical analysis. *Life Sci.* 2001;70:629-638.
  65. Eichinger A, Nasreen A, Kim HJ, Skerra A. Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D. *J Biol Chem.* 2007;282:31068-31075.
  66. Breustedt DA, Schonfeld DL, Skerra A. Comparative ligand-binding analysis of ten human lipocalins. *Biochim Biophys Acta.* 2006;1764:161-173.
  67. Morais Cabral JH, Atkins GL, Sanchez LM, Lopez-Boado YS, Lopez-Otin C, Sawyer L. Arachidonic acid binds to apolipoprotein D: implications for the protein's function. *FEBS Lett.* 1995;366:53-56.



68. Vogt M, Skerra A. Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H. *J Mol Recognit.* 2001;14:79-86.
69. Camato R, Marcel YL, Milne RW, Lussier-Cacan S, Weech PK. Protein polymorphism of a human plasma apolipoprotein D antigenic epitope. *J Lipid Res.* 1989;30:865-875.
70. Huang Y, Weisgraber KH, Mucke L, Mahley RW. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. *J Mol Neurosci.* 2004;23:189-204.
71. Dergunov AD. Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo- and hypertriglyceridemia. *Biochemistry (Mosc).* 2004;69:720-737.
72. Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. *Am J Hum Genet.* 1980;32:339-347.
73. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. *Trends Biochem Sci.* 2006;31:445-454.
74. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science.* 1993;261:921-923.
75. Zhong N, Weisgraber KH. Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. *J Biol Chem.* 2009;284:6027-6031.
76. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. *Lancet.* 2001;358:2026-2033.
77. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence. *J Intern Med.* 2006;259:493-519.
78. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and

- apolipoprotein B in the prediction of coronary heart disease in men. *Circulation*. 2005;112:3375-3383.
79. Gotto AM, Jr., Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Circulation*. 2000;101:477-484.
  80. Francis MC, Frohlich JJ. Coronary artery disease in patients at low risk--apolipoprotein AI as an independent risk factor. *Atherosclerosis*. 2001;155:165-170.
  81. Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. *Arterioscler Thromb Vasc Biol*. 2002;22:1155-1161.
  82. Ahnstrom J, Axler O, Jauhiainen M, Salomaa V, Havulinna AS, Ehnholm C, Frikke-Schmidt R, Tybjaerg-Hansen A, Dahlback B. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. *J Lipid Res*. 2008;49:1912-1917.
  83. Åkerström B, Borregaard N, Flower DR, Salier JP. *Lipocalins*. Georgetown: Landes Bioscience; 2006.
  84. Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. *Biochim Biophys Acta*. 2000;1482:9-24.
  85. Flower DR. The lipocalin protein family: structure and function. *Biochem J*. 1996;318 ( Pt 1):1-14.
  86. Bishop RE. The bacterial lipocalins. *Biochim Biophys Acta*. 2000;1482:73-83.
  87. Leone MG, Haq HA, Saso L. Lipocalin type prostaglandin D-synthase: which role in male fertility? *Contraception*. 2002;65:293-295.
  88. Akerstrom B, Logdberg L, Berggard T, Osmark P, Lindqvist A. alpha(1)-Microglobulin: a yellow-brown lipocalin. *Biochim Biophys Acta*. 2000;1482:172-184.

89. Cavaggioni A, Mucignat-Caretta C. Major urinary proteins, alpha(2U)-globulins and aphrodisin. *Biochim Biophys Acta*. 2000;1482:218-228.
90. Zanotti G, Berni R. Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. *Vitam Horm*. 2004;69:271-295.
91. Logdberg L, Wester L. Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. *Biochim Biophys Acta*. 2000;1482:284-297.
92. Flower DR. The lipocalin protein family: a role in cell regulation. *FEBS Lett*. 1994;354:7-11.
93. Xu S, Venge P. Lipocalins as biochemical markers of disease. *Biochim Biophys Acta*. 2000;1482:298-307.
94. Flower DR. Multiple molecular recognition properties of the lipocalin protein family. *J Mol Recognit*. 1995;8:185-195.
95. Akerstrom B, Flower DR, Salier JP. Lipocalins: unity in diversity. *Biochim Biophys Acta*. 2000;1482:1-8.
96. Schlehuber S, Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". *Drug Discov Today*. 2005;10:23-33.
97. Salier JP. Chromosomal location, exon/intron organization and evolution of lipocalin genes. *Biochim Biophys Acta*. 2000;1482:25-34.
98. Grzyb J, Latowski D, Strzalka K. Lipocalins - a family portrait. *J Plant Physiol*. 2006;163:895-915.
99. Calderone V, Berni R, Zanotti G. High-resolution structures of retinol-binding protein in complex with retinol: pH-induced protein structural changes in the crystal state. *J Mol Biol*. 2003;329:841-850.
100. Greene LH, Chrysina ED, Irons LI, Papageorgiou AC, Acharya KR, Brew K. Role of conserved residues in structure and stability: tryptophans of human serum retinol-binding protein, a model for the lipocalin superfamily. *Protein Sci*. 2001;10:2301-2316.
101. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. *Mol Cell*. 2002;10:1033-1043.

102. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. *Biochim Biophys Acta*. 2000;1482:272-283.
103. Bocskei Z, Groom CR, Flower DR, Wright CE, Phillips SE, Cavaggioni A, Findlay JB, North AC. Pheromone binding to two rodent urinary proteins revealed by X-ray crystallography. *Nature*. 1992;360:186-188.
104. Newcomer ME, Ong DE. Plasma retinol binding protein: structure and function of the prototypic lipocalin. *Biochim Biophys Acta*. 2000;1482:57-64.
105. Paesen GC, Adams PL, Nuttall PA, Stuart DL. Tick histamine-binding proteins: lipocalins with a second binding cavity. *Biochim Biophys Acta*. 2000;1482:92-101.
106. Borghoff SJ, Short BG, Swenberg JA. Biochemical mechanisms and pathobiology of alpha 2u-globulin nephropathy. *Annu Rev Pharmacol Toxicol*. 1990;30:349-367.
107. Gutierrez G, Ganfornina MD, Sanchez D. Evolution of the lipocalin family as inferred from a protein sequence phylogeny. *Biochim Biophys Acta*. 2000;1482:35-45.
108. Skerra A. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. *Febs J*. 2008;275:2677-2683.
109. Skerra A. Lipocalins as a scaffold. *Biochim Biophys Acta*. 2000;1482:337-350.
110. Skerra A. Alternative non-antibody scaffolds for molecular recognition. *Curr Opin Biotechnol*. 2007;18:295-304.
111. Xu N, Dahlback B. A novel human apolipoprotein (apoM). *J Biol Chem*. 1999;274:31286-31290.
112. Zhang XY, Jiao GQ, Hurtig M, Dong X, Zheng L, Luo GH, Nilsson-Ehle P, Ye Q, Xu N. Expression pattern of apolipoprotein M during mouse and human embryogenesis. *Acta Histochem*. 2004;106:123-128.
113. Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekstrom U, Nilsson-Ehle P, Ye Q, Xu N. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. *Acta Histochem*. 2003;105:67-72.

114. Ahnstrom J, Faber K, Axler O, Dahlback B. Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. *J Lipid Res.* 2007;48:1754-1762.
115. Duan J, Dahlback B, Villoutreix BO. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. *FEBS Lett.* 2001;499:127-132.
116. Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, Dahlback B, Nielsen LB. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. *J Biol Chem.* 2008;283:1839-1847.
117. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlback B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. *J Lipid Res.* 2006;47:1833-1843.
118. Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C. Infection and inflammation decrease apolipoprotein M expression. *Atherosclerosis.* 2008;199:19-26.
119. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. *Nat Med.* 2005;11:418-422.
120. Deakin JE, Papenfuss AT, Belov K, Cross JG, Coghill P, Palmer S, Sims S, Speed TP, Beck S, Graves JA. Evolution and comparative analysis of the MHC Class III inflammatory region. *BMC Genomics.* 2006;7:281.
121. Xie T, Rowen L, Aguado B, Ahearn ME, Madan A, Qin S, Campbell RD, Hood L. Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse. *Genome Res.* 2003;13:2621-2636.
122. Giuffrida FM, Reis AF. Genetic and clinical characteristics of maturity-onset diabetes of the young. *Diabetes Obes Metab.* 2005;7:318-326.
123. Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, Breslow JL, Stoffel M. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. *Nat Genet.* 2001;27:375-382.

124. Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT, Stoffel M. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. *Diabetes*. 2003;52:2989-2995.
125. Faber K, Axler O, Dahlback B, Nielsen LB. Characterization of apoM in normal and genetically modified mice. *J Lipid Res*. 2004;45:1272-1278.
126. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T, Groop L, Dahlbäck B, Karlsson E. An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. *Journal of Internal Medicine*. 2009;Epub ahead of print.
127. Skupien J, Kepka G, Gorczynska-Kosiorz S, Gebaska A, Klupa T, Wanic K, Nowak N, Borowiec M, Sieradzki J, Malecki MT. Evaluation of Apolipoprotein M Serum Concentration as a Biomarker of HNF-1alpha MODY. *Rev Diabet Stud*. 2007;4:231-235.
128. Nitta M, Ku S, Brown C, Okamoto AY, Shan B. CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene. *Proc Natl Acad Sci U S A*. 1999;96:6660-6665.
129. del Castillo-Olivares A, Gil G. Alpha 1-fetoprotein transcription factor is required for the expression of sterol 12alpha -hydroxylase, the specific enzyme for cholic acid synthesis. Potential role in the bile acid-mediated regulation of gene transcription. *J Biol Chem*. 2000;275:17793-17799.
130. Delerive P, Galardi CM, Bisi JE, Nicodeme E, Goodwin B. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. *Mol Endocrinol*. 2004;18:2378-2387.
131. Luo Y, Liang CP, Tall AR. The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor. *J Biol Chem*. 2001;276:24767-24773.
132. Schoonjans K, Annicotte JS, Huby T, Botrugno OA, Fayard E, Ueda Y, Chapman J, Auwerx J. Liver receptor homolog

- 1 controls the expression of the scavenger receptor class B type I. *EMBO Rep.* 2002;3:1181-1187.
133. Venter N, Smith JC, Goodwin B, Delerive P. Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response. *Mol Cell Biol.* 2006;26:6799-6807.
  134. Venter N, Haroniti A, Tousaint JJ, Talianidis I, Delerive P. Regulation of Anti-atherogenic Apolipoprotein M Gene Expression by the Orphan Nuclear Receptor LRH-1. *J Biol Chem.* 2008;283:3694-3701.
  135. Friedman JR, Kaestner KH. The Foxa family of transcription factors in development and metabolism. *Cell Mol Life Sci.* 2006;63:2317-2328.
  136. Li Z, White P, Tuteja G, Rubins N, Sackett S, Kaestner KH. Foxa1 and Foxa2 regulate bile duct development in mice. *J Clin Invest.* 2009;119:1537-1545.
  137. Gao N, LeLay J, Vatamaniuk MZ, Rieck S, Friedman JR, Kaestner KH. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. *Genes Dev.* 2008;22:3435-3448.
  138. Kaestner KH, Lee KH, Schlondorff J, Hiemisch H, Monaghan AP, Schutz G. Six members of the mouse forkhead gene family are developmentally regulated. *Proc Natl Acad Sci U S A.* 1993;90:7628-7631.
  139. Wan H, Dingle S, Xu Y, Besnard V, Kaestner KH, Ang SL, Wert S, Stahlman MT, Whitsett JA. Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis. *J Biol Chem.* 2005;280:13809-13816.
  140. Lee CS, Friedman JR, Fulmer JT, Kaestner KH. The initiation of liver development is dependent on Foxa transcription factors. *Nature.* 2005;435:944-947.
  141. Wolfrum C, Howell J, Ndungo E, Stoffel M. Foxa2 activity increases plasma HDL levels by regulating apolipoprotein M. *J Biol Chem.* 2008.
  142. Xu N, Hurtig M, Zhang XY, Ye Q, Nilsson-Ehle P. Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells. *Biochim Biophys Acta.* 2004;1683:33-37.
  143. Xu N, Zhang XY, Dong X, Ekstrom U, Ye Q, Nilsson-Ehle P. Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of

- apolipoprotein M in HepG2 cells. *Biochem Biophys Res Commun.* 2002; 292:944-950.
144. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. *Annu Rev Physiol.* 2006;68:159-191.
  145. Zhang Y, Mangelsdorf DJ. LXRs of lipid homeostasis: the unity of nuclear hormone receptors, transcription regulation, and cholesterol sensing. *Mol Interv.* 2002;2:78-87.
  146. Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P, Xu N. Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. *Biochem Biophys Res Commun.* 2008;371:114-117.
  147. Schmitz G, Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. *Biochim Biophys Acta.* 2005;1735:1-19.
  148. Calayir E, Becker TM, Kratzer A, Ebner B, Panzenbock U, Stefujl J, Kostner GM. LXR-agonists regulate ApoM expression differentially in liver and intestine. *Curr Pharm Biotechnol.* 2008;9:516-521.
  149. Nishina PM, Lowe S, Wang J, Paigen B. Characterization of plasma lipids in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. *Metabolism.* 1994;43: 549-553.
  150. Liang CP, Tall AR. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. *J Biol Chem.* 2001;276:49066-49076.
  151. Xu N, Nilsson-Ehle P, Hurtig M, Ahren B. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. *Biochem Biophys Res Commun.* 2004;321: 916-921.
  152. Luo G, Hurtig M, Zhang X, Nilsson-Ehle P, Xu N. Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. *Biochim Biophys Acta.* 2005;1734:198-202.
  153. Sevvana M, Ahnstrom J, Egerer-Sieber C, Dahlback B, Muller YA. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M



. *Manuscript*.

154. Lynch KR, Macdonald TL. Sphingosine 1-phosphate chemical biology. *Biochim Biophys Acta*. 2008;1781:508-512.
155. Argraves KM, Argraves WS. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. *J Lipid Res*. 2007;48:2325-2333.
156. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, Ui M, Okajima F. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. *Biochem J*. 2000;352 Pt 3:809-815.
157. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. *Cardiovasc Res*. 2009;82:201-211.
158. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. *J Lipid Res*. 1992;33:141-166.
159. Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. *Biochim Biophys Acta*. 1999;1440:1-31.
160. Olofsson SO, Bjursell G, Bostrom K, Carlsson P, Elovson J, Protter AA, Reuben MA, Bondjers G. Apolipoprotein B: structure, biosynthesis and role in the lipoprotein assembly process. *Atherosclerosis*. 1987;68:1-17.
161. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. *J Lipid Res*. 2001;42:1346-1367.
162. Frank PG, Marcel YL. Apolipoprotein A-I: structure-function relationships. *J Lipid Res*. 2000;41:853-872.
163. Martin DD, Budamagunta MS, Ryan RO, Voss JC, Oda MN. Apolipoprotein A-I assumes a "looped belt" conformation on reconstituted high density lipoprotein. *J Biol Chem*. 2006; 281:20418-20426.
164. Dahlback B, Ahnstrom J, Christoffersen C, Nielsen LB. Apolipoprotein M: structure and function. *Future Lipidology*. 2008;3:495-503.

165. Nielsen LB, Christoffersen C, Ahnstrom J, Dahlback B. ApoM: gene regulation and effects on HDL metabolism. *Trends Endocrinol Metab.* 2009.
166. Axler O, Ahnstrom J, Dahlback B. Apolipoprotein M associates to lipoproteins through its retained signal peptide. *FEBS Lett.* 2008.
167. Tuteja R. Type I signal peptidase: an overview. *Arch Biochem Biophys.* 2005;441:107-111.
168. Dalbey RE, Lively MO, Bron S, van Dijk JM. The chemistry and enzymology of the type I signal peptidases. *Protein Sci.* 1997;6:1129-1138.
169. Hegner M, von Kieckebusch-Guck A, Falchetto R, James P, Semenza G, Mantei N. Single amino acid substitutions can convert the uncleaved signal-anchor of sucrase-isomaltase to a cleaved signal sequence. *J Biol Chem.* 1992;267:16928-16933.
170. Ahnstrom J, Axler O, Dahlback B. HDL stimulates apoM secretion. *Manuscript.*
171. Christoffersen C, Ahnstrom J, Axler O, Christensen EI, Dahlback B, Nielsen LB. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. *J Biol Chem.* 2008.
172. Davidson W, Silva R, Chantepie S, Lagor W, Chapman M, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. *Atherosclerosis Supplements.* 2009;10.
173. Chapman M, Kontush A, Davidson S. Insights into HDL function from lipidomic and proteomic analyses. *Atherosclerosis Supplements.* 2009;10.
174. Kontush A, Therond P, Zerrad A, Couturier M, Negre-Salvayre A, de Souza JA, Chantepie S, Chapman MJ. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. *Arterioscler Thromb Vasc Biol.* 2007; 27:1843-1849.
175. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II: mapping of proteins in high-density

- lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. *Proteomics*. 2005;5:1431-1445.
176. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. *Proteomics*. 2005;5:551-565.
  177. Karlsson H, Lindqvist H, Tagesson C, Lindahl M. Characterization of apolipoprotein M isoforms in low-density lipoprotein. *J Proteome Res*. 2006;5:2685-2690.
  178. Christensen EI. Pathophysiology of protein and vitamin handling in the proximal tubule. *Nephrol Dial Transplant*. 2002;17 Suppl 9:57-58.
  179. Verroust PJ, Christensen EI. Megalin and cubilin--the story of two multipurpose receptors unfolds. *Nephrol Dial Transplant*. 2002;17:1867-1871.
  180. Christensen EI, Moskaug JO, Vorum H, Jacobsen C, Gundersen TE, Nykjaer A, Blomhoff R, Willnow TE, Moestrup SK. Evidence for an essential role of megalin in transepithelial transport of retinol. *J Am Soc Nephrol*. 1999; 10:685-695.
  181. Christensen EI, Verroust PJ. Megalin and cubilin, role in proximal tubule function and during development. *Pediatr Nephrol*. 2002;17:993-999.
  182. Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C, Aucouturier P, Moskaug JO, Otto A, Christensen EI, Willnow TE. Megalin knockout mice as an animal model of low molecular weight proteinuria. *Am J Pathol*. 1999;155:1361-1370.
  183. Faber K, Hvidberg V, Moestrup SK, Dahlback B, Nielsen LB. Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. *Mol Endocrinol*. 2006;20:212-218.
  184. Plomgaard P, Dullaart RP, de Vries R, Groen AK, Dahlback B, Nielsen LB. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects. *J Intern Med*. 2009.
  185. Xu X, Ye Q, Xu N, He X, Luo G, Zhang X, Zhu J, Zhang Y, Nilsson-Ehle P. Effects of ischemia-reperfusion injury on

- apolipoprotein M expression in the liver. *Transplant Proc.* 2006;38:2769-2773.
186. Axler O, Ahnstrom J, Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. *J Lipid Res.* 2007;48:1772-1780.
  187. Ahnstrom J, Gottsater A, Lindblad B, Dahlback B. Plasma concentrations of apolipoproteins A-I, B and M in patients with critical limb ischemia. *Manuscript.*
  188. Jiang J, Zhang X, Wu C, Qin X, Luo G, Deng H, Lu M, Xu B, Li M, Ji M, Xu N. Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases. *Lipids Health Dis.* 2008;7:25.
  189. Xu N, Nilsson-Ehle P, Ahren B. Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin. *Biochem Biophys Res Commun.* 2006;342:1174-1177.
  190. Xu N, Ahren B, Jiang J, Nilsson-Ehle P. Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. *Biochim Biophys Acta.* 2006;1761:256-260.
  191. Zhang X, Jiang B, Luo G, Nilsson-Ehle P, Xu N. Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. *Biochim Biophys Acta.* 2007;1771:879-882.
  192. Niu N, Zhu X, Liu Y, Du T, Wang X, Chen D, Sun B, Gu HF, Liu Y. Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese. *Diabetes Metab Res Rev.* 2007;23:21-25.
  193. Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. *J Am Soc Nephrol.* 2000;11 Suppl 16:S140-143.
  194. Guize L, Pannier B, Thomas F, Bean K, Jegu B, Benetos A. Recent advances in metabolic syndrome and cardiovascular disease. *Arch Cardiovasc Dis.* 2008;101:577-583.
  195. Taslim S, Tai ES. The relevance of the metabolic syndrome. *Ann Acad Med Singapore.* 2009;38:29-25.

196. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech.* 2009;2:231-237.
197. Dullaart RP, Plomgaard P, de Vries R, Dahlback B, Nielsen LB. Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. *Clin Chim Acta.* 2009.
198. Xu N, Nilsson-Ehle P, Ahren B. Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. *J Nutr Biochem.* 2004;15:579-582.
199. Jiao GQ, Yuan ZX, Xue YS, Yang CJ, Lu CB, Lu ZQ, Xiao MD. A prospective evaluation of apolipoprotein M gene T-778C polymorphism in relation to coronary artery disease in Han Chinese. *Clin Biochem.* 2007;40:1108-1112.
200. Xu WW, Zhang Y, Tang YB, Xu YL, Zhu HZ, Ferro A, Ji Y, Chen Q, Fan LM. A Genetic Variant of Apolipoprotein M Increases Susceptibility to Coronary Artery Disease in a Chinese Population. *Clin Exp Pharmacol Physiol.* 2007.
201. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. *Ann Intern Med.* 1971;74:1-12.
202. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. *Am Heart J.* 1986;112:825-836.
203. Salomaa V, Rasi V, Pekkanen J, Vahtera E, Jauhiainen M, Vartiainen E, Myllyla G, Ehnholm C. Haemostatic factors and prevalent coronary heart disease; the FINRISK Haemostasis Study. *Eur Heart J.* 1994;15:1293-1299.
204. Salomaa VV, Rasi VP, Vahtera EM, Pekkanen J, Pursiainen M, Jauhiainen M, Vartiainen E, Ehnholm CP, Myllyla G. Haemostatic factors and lipoprotein (a) in three geographical areas in Finland: the Finrisk Haemostasis Study. *J Cardiovasc Risk.* 1994;1:241-248.
205. Appleyard M, Hansen AT, Jensen G, Schnorh P, Nyboe J. The Copenhagen City Heart Study. Østerbroundersoegelsen. A book of tables with data from the first examination (1976-78) and a five year follow-up

- (1981-83). The Copenhagen City Heart Study Group. *Scand J Soc Med Suppl.* 1989;41:1-160.
206. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study, Østerbroundersoegelsen, tables with data from the third examination 1991-1994. *Eur Heart J Suppl.* 2001;3(Suppl H):1-83.
  207. Su W, Jiao G, Yang C, Ye Y. Evaluation of apolipoprotein M as a biomarker of coronary artery disease. *Clin Biochem.* 2009;42:365-370.
  208. Hamilton JA. Fatty acid interactions with proteins: what X-ray crystal and NMR solution structures tell us. *Prog Lipid Res.* 2004;43:177-199.
  209. Deakin S, Leviev I, Gomaschi M, Calabresi L, Franceschini G, James RW. Enzymatically active para-oxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. *J Biol Chem.* 2002;277:4301-4308.
  210. van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. *Curr Opin Lipidol.* 2007;18:147-151.
  211. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. *Eur J Clin Invest.* 1996;26:427-435.
  212. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. *J Clin Invest.* 1995;96:2758-2767.